A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200, an Ectodysplasin-A1 Replacement Molecule, in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Adults

Trial Profile

A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200, an Ectodysplasin-A1 Replacement Molecule, in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2013

At a glance

  • Drugs EDI 200 (Primary)
  • Indications Ectodermal dysplasia
  • Focus Adverse reactions
  • Sponsors Edimer Pharmaceuticals
  • Most Recent Events

    • 26 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Oct 2013 Status changed from recruiting to active, no longer recruiting, as reported by an Edimer Pharmaceuticals media release.
    • 09 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top